{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T07:52:38Z","timestamp":1784879558748,"version":"3.55.0"},"reference-count":23,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100009592","name":"Beijing Municipal Science and Technology Commission, Adminitrative Commission of Zhongguancun Science Park","doi-asserted-by":"publisher","award":["D171100002617003"],"award-info":[{"award-number":["D171100002617003"]}],"id":[{"id":"10.13039\/501100009592","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","redjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.ijrobp.2025.11.046","type":"journal-article","created":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T16:31:35Z","timestamp":1764865895000},"page":"489-501","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["CapeOX Versus Capecitabine in Neoadjuvant Chemoradiation for High-Risk Locally Advanced Rectal Cancer: Long-Term Results From the MONT-R Randomized Controlled Trial"],"prefix":"10.1016","volume":"125","author":[{"given":"Jiaolin","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ganbin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenzhuo","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aiwen","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenjun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongwei","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiancheng","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiagang","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guocong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenya","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huadan","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weixun","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianfeng","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Miao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjuan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junyang","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beizhan","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Cong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiyu","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lai","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guannan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huizhong","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guole","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2025.11.046_bib0001","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/s41575-020-0275-y","article-title":"The multidisciplinary management of rectal cancer","volume":"17","author":"Keller","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"suppl 4","key":"10.1016\/j.ijrobp.2025.11.046_bib0002","doi-asserted-by":"crossref","first-page":"iv22","DOI":"10.1093\/annonc\/mdx224","article-title":"Rectal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Glynne-Jones","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ijrobp.2025.11.046_bib0003","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/S1470-2045(13)70599-0","article-title":"Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: Long-term results of the EORTC 22921 randomised study","volume":"15","author":"Bosset","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2025.11.046_bib0004","doi-asserted-by":"crossref","first-page":"4620","DOI":"10.1200\/JCO.2006.06.7629","article-title":"Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: Results of FFCD 9203","volume":"24","author":"G\u00e9rard","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2025.11.046_bib0005","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1200\/JCO.2003.11.126","article-title":"Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: Interim results of a phase III trial","volume":"21","author":"Rothenberg","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2025.11.046_bib0006","doi-asserted-by":"crossref","first-page":"2198","DOI":"10.1200\/JCO.2006.08.2974","article-title":"Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07","volume":"25","author":"Kuebler","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2025.11.046_bib0007","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1200\/JCO.2009.25.8376","article-title":"Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: Results of the phase III trial ACCORD 12\/0405-Prodige 2","volume":"28","author":"G\u00e9rard","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2025.11.046_bib0009","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1200\/JCO.2013.53.7753","article-title":"Capecitabine and oxaliplatin in the preoperative multimodality treatment of rectal cancer: Surgical end points from National Surgical Adjuvant Breast and Bowel Project trial R-04","volume":"32","author":"O'Connell","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2025.11.046_bib0010","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1200\/JCO.2010.34.4911","article-title":"Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: Pathologic results of the STAR-01 randomized phase III trial","volume":"29","author":"Aschele","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2025.11.046_bib0008","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S1470-2045(12)70187-0","article-title":"Preoperative chemoradiotherapy and postoperative chemotherapy with fluorouracil and oxaliplatin versus fluorouracil alone in locally advanced rectal cancer: Initial results of the German CAO\/ARO\/AIO-04 randomised phase 3 trial","volume":"13","author":"R\u00f6del","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2025.11.046_bib0011","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1200\/JCO.20.01740","article-title":"Pre- and postoperative capecitabine without or with oxaliplatin in locally advanced rectal cancer: PETACC 6 Trial by EORTC GITCG and ROG, AIO, AGITG, BGDO, and FFCD","volume":"39","author":"Schmoll","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2025.11.046_bib0012","first-page":"588","article-title":"Fluorouracil-based preoperative chemoradiotherapy with or without oxaliplatin for stage II\/III rectal cancer: a 3-year follow-up study","volume":"27","author":"Jiao","year":"2015","journal-title":"Chin J Cancer Res"},{"key":"10.1016\/j.ijrobp.2025.11.046_bib0013","doi-asserted-by":"crossref","first-page":"3223","DOI":"10.1200\/JCO.18.02309","article-title":"Neoadjuvant modified folfox6 with or without radiation versus fluorouracil plus radiation for locally advanced rectal cancer: Final results of the Chinese FOWARC trial","volume":"37","author":"Deng","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2025.11.046_bib0014","doi-asserted-by":"crossref","first-page":"4558","DOI":"10.1200\/JCO.2012.42.8771","article-title":"Clinical outcome of the ACCORD 12\/0405 PRODIGE 2 randomized trial in rectal cancer","volume":"30","author":"G\u00e9rard","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2025.11.046_bib0015","doi-asserted-by":"crossref","first-page":"3770","DOI":"10.1200\/JCO.21.02017","article-title":"Linking the European organisation for research and treatment of cancer item library to the common terminology criteria for adverse events","volume":"40","author":"Gilbert","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2025.11.046_bib0016","doi-asserted-by":"crossref","first-page":"719","DOI":"10.6004\/jnccn.2015.0087","article-title":"Rectal cancer, Version 2.2015","volume":"13","author":"Benson","year":"2015","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.ijrobp.2025.11.046_bib0017","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/S1470-2045(15)00159-X","article-title":"Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO\/ARO\/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial","volume":"16","author":"R\u00f6del","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2025.11.046_bib0018","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/S1470-2045(21)00079-6","article-title":"Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial","volume":"22","author":"Conroy","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2025.11.046_bib0019","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1200\/JCO.2011.39.7901","article-title":"Neoadjuvant treatment response as an early response indicator for patients with rectal cancer","volume":"30","author":"Park","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2025.11.046_bib0020","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1200\/JCO.2013.54.3769","article-title":"Tumor regression grading after preoperative chemoradiotherapy for locally advanced rectal carcinoma revisited: updated results of the CAO\/ARO\/AIO-94 trial","volume":"32","author":"Fokas","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2025.11.046_bib0023","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/j.annonc.2024.06.019","article-title":"Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiotherapy in patients with locally advanced rectal cancer: long-term results of the UNICANCER-PRODIGE 23 trial","volume":"35","author":"Conroy","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ijrobp.2025.11.046_bib0024","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1470-2045(20)30555-6","article-title":"Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial","volume":"22","author":"Bahadoer","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2025.11.046_bib0025","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2018.0071","article-title":"Adoption of total neoadjuvant therapy for locally advanced rectal cancer","volume":"4","author":"Cercek","year":"2018","journal-title":"JAMA Oncol"}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301625065319?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301625065319?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T08:19:56Z","timestamp":1780388396000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360301625065319"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":23,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S0360301625065319"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2025.11.046","relation":{},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CapeOX Versus Capecitabine in Neoadjuvant Chemoradiation for High-Risk Locally Advanced Rectal Cancer: Long-Term Results From the MONT-R Randomized Controlled Trial","name":"articletitle","label":"Article Title"},{"value":"International Journal of Radiation Oncology*Biology*Physics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijrobp.2025.11.046","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}